Spotlight Innovation Inc. (OTCMKTS:STLT) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On January 27, 2017, Spotlight Innovation Inc. (the Company)
entered into a second Exclusive License Agreement (the License
Agreement) with Florida State University Research Foundation to
commercialize certain compounds that may have therapeutic
potential for treating viral infections, including Zika virus
infection. The Company will file a copy of the License Agreement
with its Annual Report on Form 10-K for the year ended December
31, 2016 in redacted form subject to an application for
confidential treatment the Company is making with the Securities
and Exchange Commission.
About Spotlight Innovation Inc. (OTCMKTS:STLT)
Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The Company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. and Memcine Pharmaceuticals, Inc. Through its subsidiary, Celtic Biotech Iowa, Inc., it develops a range of drug candidates, such as Crotoxin, Cardiotoxin, VRCTC310 and Crotamine. Through its subsidiary, Memcine Pharmaceuticals, Inc., it offers Immunoplex. Spotlight Innovation Inc. (OTCMKTS:STLT) Recent Trading Information
Spotlight Innovation Inc. (OTCMKTS:STLT) closed its last trading session 00.000 at 0.510 with 16,092 shares trading hands.
